In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Nordion

ObsEva Slashes 70% Of Staff To Survive

Having surrendered the rights to linzagolix, its GnRH antagonist for bleeding associated with uterine fibroids that the FDA blocked, ObsEva is showing the door to most of its staff in a bid to cut costs and keep in business.

Restructuring Gynecology & Urology

Deal Watch: Roche, PhoreMost Enter Into Multi-Target Collaboration

Plus deals with Synaffix/Emergence, Helsinn/Juniper and Sanyou/Shanghai KangaBio, while Takeda/Finch and Dong-A/Beactica ended prior collaborations. 

Deals Business Strategies

ObsEva Ends Linzagolix Launch Plans, Casting Another Shadow Over Women's Health

The Swiss drug maker will initiate a "mass dismissal" and return rights to its lead drug candidate after the US FDA alerted the company to NDA deficiencies.

Gynecology & Urology Business Strategies

Asia Deal Watch: Rona Takes On Sanofi’s siRNA Platform

Rona hopes technology acquired from Sanofi will enhance its RNA capabilities in liver and non-liver indications. NeuroFront gets Greater China and Singapore rights to Novaremed’s neuropathic pain drug.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Medical Devices
  • Other Names / Subsidiaries
    • MDS Inc.
UsernamePublicRestriction

Register